Lake Oswego, Portland--(Newsfile Corp. - May 6, 2026) - Functional Brands Inc. (NASDAQ: MEHA), a pioneer in next-generation health and wellness solutions, today announced the official launch of GLP-Squared Injection, its groundbreaking dual-peptide injectable combining Semaglutide and Tirzepatide in a single, synergistic formulation. GLP-Squared is now exclusively available to members of the Company's flagship digital health platform, Tru2u.health.

"The introduction of GLP-Squared Injection is a transformational milestone for Functional Brands and the members of Tru2u.health. By combining two of the most clinically effective peptides in metabolic medicine into a single, physician-guided protocol, we are offering our members a powerful new tool to achieve their health goals. Tru2u.health was built to be the home of innovation in personalized health, and GLP-Squared exemplifies exactly that commitment," said Eric Gripentrog, CEO of Functional Brands Inc.

A New Standard in GLP-1-Based Metabolic Therapy

GLP-Squared Injection represents a significant advancement in metabolic and weight-management medicine. By combining Semaglutide-a proven GLP-1 receptor agonist-with Tirzepatide's dual GLP-1/GIP receptor agonist activity, the formulation is designed to deliver amplified appetite regulation, improved glycemic control, and enhanced adipose tissue reduction through complementary and synergistic mechanisms of action.

The goal of offering patients a precision-optimized, clinician-supervised peptide therapy that goes beyond what single-agent GLP-1 products can achieve.

Key Highlights: GLP-Squared Injection

• Dual-Mechanism Action: Combines Semaglutide (GLP-1 agonist) with Tirzepatide (GLP-1 + GIP dual agonist) for a multi-receptor metabolic impact that addresses appetite, insulin sensitivity, and fat metabolism simultaneously.

• Precision Peptide Formulation: Clinically calibrated dosing ratios developed to maximize synergy while maintaining an individualized safety profile for each Tru2u.health member.

• Clinician-Supervised Protocol: GLP-Squared is prescribed and monitored by licensed healthcare providers through the Tru2u.health telehealth infrastructure, ensuring medically appropriate oversight at every step.

• Platform-Exclusive Access: GLP-Squared Injection is exclusively available through Tru2u.health, underscoring the Company's commitment to integrating cutting-edge therapeutics within its personalized digital health ecosystem.

• Streamlined Member Experience: From initial consultation and labs to prescription fulfillment and ongoing coaching, members receive end-to-end support directly through the Tru2u.health platform.

Tru2u.health: The Platform Powering Personalized Health at Scale

Tru2u.health is Functional Brands' proprietary digital health platform designed to connect members with licensed clinicians, evidence-based therapeutics, and personalized wellness protocols-all in one place. Tru2u.health serves as the exclusive conduit for GLP-Squared Injection, allowing members to:

• Complete telehealth consultations with credentialed providers

• Access required laboratory screening and results review

• Receive GLP-Squared prescriptions with direct fulfillment

• Engage with ongoing metabolic coaching, nutrition guidance, and progress monitoring

• Benefit from a fully integrated, data-driven health journey personalized to their biology and goals

The launch of GLP-Squared on Tru2u.health marks a pivotal expansion of the platform's therapeutic offerings, reinforcing its position as a premier destination for members seeking clinically sophisticated, results-driven health optimization.

Addressing a Multi-Billion Dollar Market Opportunity

The global GLP-1 therapy market is among the fastest-growing segments in healthcare, with demand for Semaglutide and Tirzepatide-based therapies continuing to accelerate. Functional Brands is strategically positioned to capture meaningful market share through the Tru2u.health platform, which offers a differentiated, end-to-end member experience that commodity pharmacy channels cannot replicate.

GLP-Squared Injection further distinguishes Tru2u.health by offering a proprietary dual-peptide option not available through traditional retail or mail-order pharmacy routes, creating a meaningful competitive moat and a compelling driver of member acquisition and retention.

Availability

GLP-Squared Injection is available immediately to qualifying Tru2u.health members following clinician evaluation and approval. Interested individuals may visit www.Tru2u.health to begin their intake, complete telehealth onboarding, and determine eligibility for the GLP-Squared protocol.

About Functional Brands Inc. (MEHA)

Functional Brands Inc. (NASDAQ: MEHA) is a health and wellness company dedicated to delivering innovative, evidence-based therapeutic solutions through its proprietary digital platform, Tru2u.health. The Company's mission is to make clinically meaningful health optimization accessible, personalized, and scalable for every member. Functional Brands develops and distributes a curated portfolio of functional health products, peptide therapies, and telehealth services designed to support metabolic health, longevity, and overall wellbeing.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those implied by the forward-looking statements. Functional Brands Inc. undertakes no obligation to publicly update or revise any forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296153

Source: Functional Brands Inc.